P Libby, J Plutzky - The American Journal of Cardiology, 2007 - Elsevier Patients with type 2 diabetes mellitus and/or the metabolic syndrome have
considerable cardiovascular risk. Treatment with 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitors (statins) and with antihypertensive and ... Cited by 58 - Related articles - All 32 versions
- Free from Publisher DM Riche, R Valderrama, NN Henyan - Diabetes Care, 2007 - Am Diabetes Assoc OBJECTIVE—Thiazolidinediones (TZDs) (rosiglitazone and pioglitazone) are a
class of antidiabetes agents that have a high affinity for peroxisome
proliferator–activated receptor-γ. TZDs initiate a multitude of ... Cited by 26 - Related articles - All 6 versions
- ►onlinejacc.org D Baumgart, V Klauss, F Baer, F Hartmann, H … - Journal of the American College of Cardiology, 2007 - Elsevier This study sought to analyze the effectiveness of drug-eluting stents in a
high-risk group of diabetic patients. Previously, this had been analyzed only in
substudies of larger trials or in clinical investigations enrolling a small ... Cited by 20 - Related articles - All 12 versions
ES Rosmarakis, ME Falagas - American Heart Journal, 2007 - Elsevier Five RCTs that included 235 evaluable patients who underwent coronary stent
implantation and received a 6-month pioglitazone or rosiglitazone therapy were
included in our meta-analysis. Restenosis rate was significantly lower in ... Cited by 21 - Related articles - All 39 versions
- ►geyseco.info [PDF] E Selvin, S Bolen, HC Yeh, C Wiley, LM … - Archives of Internal Medicine, 2008 - Am Med Assoc Methods We searched MEDLINE, EMBASE, and the Cochrane Central Register of
Controlled Trials, from inception through January 19, 2006. Forty publications
of controlled trials that reported information on cardiovascular events ( ... Cited by 23 - Related articles - All 5 versions
- ►nursing2008.com [PDF] N Riera-Guardia, D Rothenbacher - Diabetes, Obesity & Metabolism, 2008 - pt.wkhealth.com Background and aims: Adiponectin is a hormone mainly produced by white adipose
tissue. Decreased levels of adiponectin are linked with visceral obesity,
insulin resistance states, and cardiovascular diseases. Recently, several ... Cited by 16 - Related articles - All 5 versions
MC Granberry, JB Hawkins, AM Franks - American Journal of Health-System Pharmacy, 2007 - medscape.com Purpose: A review of the significant findings related to the use of the
thiazolidinediones (TZDs) in the treatment of patients with type 2 diabetes
mellitus and heart failure was conducted. Summary: TZDs are ... Cited by 15 - Related articles - BL Direct - All 13 versions
- ►sherbornegibbs.com [PDF] RA Ajjan, PJ Grant - Diabetes & Vascular Disease Research, 2006 - dvr.sagepub.com Abstract M ultiple risk factor intervention is essential in order to prevent
cardiovascular (CV) disease in patients with diabetes. Therefore, to reduce
atherothrombotic events, an ideal oral anti-diabetic agent should be able ... Cited by 15 - Related articles - BL Direct - All 8 versions
- ►nursing2008.com E Mannucci, M Monami, C Lamanna, GF … - Diabetes, Obesity and Metabolism, 2008 - pt.wkhealth.com Aim: The aim of this meta-analysis of randomized clinical trials (RCT) was to
assess whether pioglitazone is also associated with increased cardiovascular
risk, as recently reported for rosiglitazone. Methods: RCT of pioglitazone ... Cited by 14 - Related articles - All 6 versions
